DXCM Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of 13.54% compared to DexCom's net margin of 27.73%. DexCom's return on equity of 30.96% beat Intuitive Surgical's return on equity of 15.9%.

DexCom has a consensus price target of $97.14, signalling upside risk potential of 15.12%. On the other hand Intuitive Surgical has an analysts' consensus of $576.97 which suggests that it could fall by -2.64%. Given that DexCom has higher upside potential than Intuitive Surgical, analysts believe DexCom is more attractive than Intuitive Surgical.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.941%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are smaller than Intuitive Surgical quarterly revenues of $2B. DexCom's net income of $134.6M is lower than Intuitive Surgical's net income of $565.1M. Notably, DexCom's price-to-earnings ratio is 50.53x while Intuitive Surgical's PE ratio is 95.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.86x versus 27.17x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical has a net margin of 13.54% compared to DexCom's net margin of -13.93%. DexCom's return on equity of 30.96% beat Orthofix Medical's return on equity of -20.83%.

DexCom has a consensus price target of $97.14, signalling upside risk potential of 15.12%. On the other hand Orthofix Medical has an analysts' consensus of -- which suggests that it could grow by 34.58%. Given that Orthofix Medical has higher upside potential than DexCom, analysts believe Orthofix Medical is more attractive than DexCom.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.972%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Orthofix Medical quarterly revenues of $196.6M. DexCom's net income of $134.6M is higher than Orthofix Medical's net income of -$27.4M. Notably, DexCom's price-to-earnings ratio is 50.53x while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.86x versus 0.88x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 13.54% compared to DexCom's net margin of 14.25%. DexCom's return on equity of 30.96% beat Insulet's return on equity of 49.55%.

DexCom has a consensus price target of $97.14, signalling upside risk potential of 15.12%. On the other hand Insulet has an analysts' consensus of $292.29 which suggests that it could grow by 5.98%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Insulet quarterly revenues of $543.9M. DexCom's net income of $134.6M is higher than Insulet's net income of $77.5M. Notably, DexCom's price-to-earnings ratio is 50.53x while Insulet's PE ratio is 47.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.86x versus 10.62x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 13.54% compared to DexCom's net margin of -9.53%. DexCom's return on equity of 30.96% beat Tandem Diabetes Care's return on equity of -47.23%.

DexCom has a consensus price target of $97.14, signalling upside risk potential of 15.12%. On the other hand Tandem Diabetes Care has an analysts' consensus of $51.10 which suggests that it could grow by 45.38%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

DexCom has a beta of 1.128, which suggesting that the stock is 12.763% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.148%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Tandem Diabetes Care quarterly revenues of $244M. DexCom's net income of $134.6M is higher than Tandem Diabetes Care's net income of -$23.3M. Notably, DexCom's price-to-earnings ratio is 50.53x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.86x versus 2.69x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.